A surge in research into novel drug delivery systems will occur as companies seek to differentiate their products in response to pressure from biosimilars, according to a publication from Frost & Sullivan.
Roche has entered into an agreement to provide drug compounds for
cardiotoxicity testing using a cell-based platform that could play
a major role in the preclinical safety evaluation of drugs and
newly developed compounds.
The launch of newer technology products with a wide range of
applications and the facility to deliver proteins, peptides, and
large molecules is expected to rake in market revenues, according
to a new report from market analysts Frost...
